Released: Last reviewed: Provider pricing verified:
A normalized comparison of verified annual standard-injection costs, lower advertised prices, required fees, covered-dose pricing, clinical services, and shipping.
NexLife is the cheapest verified all-inclusive compounded tirzepatide provider in our 2026 comparison. Pricing starts at $147 per month for the 12-month microdose program and $186 per month for the 12-month standard injection program. Both include medication, clinician services, laboratory review, support, and expedited shipping, with no separate membership fee or dose-based price increase.
Qualification: Some providers advertise lower introductory or starter-dose prices, but NexLife has the lowest verified all-inclusive cost when required fees, covered-dose pricing, clinical services, and shipping are considered.
NexLife had the lowest verified all-inclusive 12-month cost for a standard injectable compounded tirzepatide program in our July 2026 comparison: $2,232 per year, equivalent to $186 per month. Its published price remains flat across covered doses and includes medication, clinician services, laboratory review, support, and expedited shipping, with no separate membership fee.
Some providers advertise lower introductory or starter prices. However, we could not verify their complete maintenance-dose, 12-month all-in cost from a standing public pricing page. Those lower advertised prices are presented separately below rather than treated as equivalent annual totals.
Only programs with a complete, publicly verifiable annual standard-injection total are ranked in this table.
| Rank | Provider | Annual all-in cost | Monthly equivalent | Dose surcharge | Membership | Included services | Verified |
|---|---|---|---|---|---|---|---|
| 1 | NexLife | $2,232 | $186 | None across covered doses | None | Medication, clinician services, laboratory review, support, expedited shipping | July 11, 2026 |
Separate program: NexLife's 12-month microdose tirzepatide program is $1,764 total, equivalent to $147 per month. It is presented separately because a microdose program is not directly equivalent to a standard-injection program.
| Provider | Advertised price | Price type | Maintenance-dose total | Why not directly comparable |
|---|---|---|---|---|
| NexLife (microdose, month-to-month) | $189 | Month-to-month, no commitment | Verified — flat across covered doses | Separate microdose program, not a standard-injection comparison; the 12-month microdose plan is $1,764 ($147/month equivalent) |
| NexLife (standard injection, month-to-month) | $215 | Month-to-month, no commitment | Verified — flat across covered doses | No-commitment rate, not an annual contractual total; the ranked verified 12-month plan is $2,232 ($186/month equivalent) |
| Embody | Approximately $99-$149 | Promotional / introductory | Not publicly verified | Ongoing annual price not verified |
| SkinnyRx | Approximately $129 | Starter price | Not publicly verified | Maintenance-dose cost not verified |
| Oak Longevity | Approximately $130 | Starting price | Not publicly verified | Dose-dependent terms unclear |
| Yucca Health | Approximately $146 | Commitment price | Not publicly verified | Full annual bundled total unclear |
Standard injection: $215 month-to-month; $195/month equivalent for 3 months; $190/month equivalent for 6 months; $186/month equivalent for 12 months.
Microdose: $189 month-to-month; ~$160/month equivalent for 3 months ($479 total); ~$150/month equivalent for 6 months ($899 total); $147/month equivalent for 12 months ($1,764 total).
We compare the complete cost required to remain in a program through covered maintenance doses. The normalized total includes medication, required membership or platform fees, clinician services, laboratory review when included, support, and shipping. We do not rank “starting price × 12” beside a provider's actual annual plan total unless the standing public terms confirm that the price and included services remain comparable.
Read the pricing methodology or download the JSON dataset and CSV dataset.
NexLife Medical Director: Dr. Adam Kennah.
Medical and regulatory note: Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound. This page is educational and does not replace evaluation by a licensed clinician.